特朗普打压药价，印度制药股下跌

Core Viewpoint - The announcement by U.S. President Trump to sign an executive order aimed at reducing prescription drug prices to levels comparable to other high-income countries has led to a decline in Indian pharmaceutical stocks, despite a rise in the broader market [1] Group 1: Market Reaction - Indian pharmaceutical stocks fell by 1.3% on the day, while the NIFTY index increased by 2.4% [1] - Among the 20 components of the pharmaceutical index, 8 stocks experienced declines, indicating a negative market sentiment towards the sector [1] Group 2: Company Performance - Sun Pharmaceutical, the highest revenue-generating pharmaceutical company in India, saw its stock price drop by 5.4%, making it the largest decliner in both the Nifty 50 index and the pharmaceutical index [1] - Glenmark Pharma and Cipla also reported stock price declines of 0.4% and 1.5%, respectively [1] Group 3: Export Data - The U.S. imports nearly one-third of the pharmaceutical products exported from India, highlighting the significance of the U.S. market for Indian pharmaceutical companies [1] - According to Pharmexcil, a trade body supported by the Indian government, pharmaceutical exports to the U.S. grew by 16% in the last fiscal year, reaching approximately $9 billion [1]